Court orders temporary halt on Sun Pharma's $3.2 bln takeover of Ranbaxy

MUMBAI Thu May 1, 2014 12:09am IST

A Ranbaxy office building is pictured in Mohali May 14, 2013. REUTERS/Ajay Verma/files

A Ranbaxy office building is pictured in Mohali May 14, 2013.

Credit: Reuters/Ajay Verma/files

Related Topics

Stocks

   

MUMBAI (Reuters) - A court has temporarily halted generic drugmaker Sun Pharmaceutical Industries Ltd's(SUN.NS) $3.2 billion takeover of rival Ranbaxy Laboratories Ltd(RANB.NS) until it decides on a petition for a probe into alleged insider trading.

Last week, two individuals filed the petition in the high court of Andhra Pradesh, requesting the court ask the market regulator and the two main stock exchanges to halt the deal and order the probe. A copy of the petition was seen by Reuters on Wednesday.

The court then ordered an "interim status quo" on the deal and asked all the involved companies, the regulator, and the stock exchanges for details, according to an order dated April 25 and seen by Reuters on the court's website on Wednesday.

Ranbaxy shares jumped 24 percent and trading volume tripled in three sessions ahead of the companies' announcement that Sun Pharma would buy the loss-making company from Japan's Daiichi Sankyo Ltd (4568.T).

The Indian market regulator said this month it was seeking information from Ranbaxy and Sun Pharma on the transaction and would ask for stock exchange trading data after receiving "multiple complaints".

Sun Pharma and Ranbaxy are listed on both the National Stock Exchange and the Bombay Stock Exchange.

Sun Pharma said in a statement the company had not received any communication related to the court order. It also said that it had not violated any rules.

"The matter related to purchase of shares of Ranbaxy Laboratories Ltd does not violate Insider Trading Rules," Sun said, adding it would take "appropriate action" on the petition as advised by its lawyers.

Ranbaxy did not immediately respond to an email requesting comment. A spokesman for the market regulator, the Securities and Exchange Board of India (SEBI), said they had not received the court order and declined to comment further.

Shares in Sun Pharma, India's biggest drugmaker by market value, fell as much as 2.7 percent on Wednesday. The stock ended down 1.04 percent and Ranbaxy fell 2.01 percent, while the Nifty closed 0.3 percent lower.

(Reporting by Devidutta Tripathy and Zeba Siddiqui; additional reporting by Himank Sharma; Writing by Sumeet Chatterjee; Editing by Miral Fahmy)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Global Growth

Global Growth

IMF cuts outlook, warns of stagnation risk in rich nations  Full Article 

Waning Enthusiasm

Waning Enthusiasm

Markets' post-election enthusiasm lost on consumers.  Full Article 

Monsoon Revives

Monsoon Revives

Monsoon revival keeps rain above average   Full Article 

Banking Sector

Banking Sector

Banks not allowed to trade in bonds for infra lending - RBI.  Full Article 

Just Not Enough

Just Not Enough

Amazon's smartphone fails to kindle a "Fire" among reviewers.  Full Article 

Rising Market Value

Rising Market Value

Facebook goes express to mega-cap status  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage